Education
About Us
Working with TipRanks
Follow Us
Impedimed Limited (IPDQF)
OTHER OTC:IPDQF
IPDQF Stock Chart & Stats
$0.02
<$0.01(23.84%)
At close: 4:00 PM EST
$0.02
<$0.01(23.84%)
Day’s Range― - ―
52-Week Range<$0.01 - $0.05
Previous CloseN/A
Volume1.78K
Average Volume (3M)5.35K
Market Cap
$24.62M
Enterprise Value$37.75M
Total Cash (Recent Filing)$18.85M
Total Debt (Recent Filing)$21.93M
Price to Earnings (P/E)―
Beta3.16
Next Earnings
Aug 27, 2026Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding2,038,747,700
10 Day Avg. Volume16,058
30 Day Avg. Volume5,352
Financial Highlights & Ratios
PEG Ratio-0.20
Price to Book (P/B)3.45
Price to Sales (P/S)5.55
P/FCF Ratio-4.52
Enterprise Value/Market Cap1.53
Enterprise Value/Revenue2.65
Enterprise Value/Gross Profit-45.37
Enterprise Value/Ebitda-2.41
Forecast
1Y Price Target
$0.03Price Target Upside66.30% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)$11.67M
Bulls Say, Bears Say
Bulls Say
Reimbursement ExpansionMaterial expansion in reimbursement coverage reduces a major adoption barrier for BIS diagnostics. Greater coverage makes hospital purchases and routine clinical use more likely, supporting sustained device utilization, recurring follow-on revenue and broader market penetration over the coming months.
Recurring Revenue GrowthRising ARR and record revenue signal improving sales momentum and a growing base of contractually linked or repeat revenue. This strengthens predictability of cash flows and scalability of margins as installed base grows, supporting durable commercial progress beyond one-off sales.
Strong Hospital FootprintDeep penetration in leading hospitals provides clinical validation and reference sites that facilitate wider adoption. A sizable installed base creates recurring consumable/software demand, referral effects and competitive differentiation that support sustained revenue generation.
Bears Say
Negative Cash FlowPersistent negative operating and free cash flow reduces financial flexibility and increases reliance on external funding or one-time receipts. Worsening FCF growth constrains the company’s ability to invest in commercial expansion and product development over the medium term.
Unprofitable OperationsHigh gross margins indicate product-level efficiency, but heavy operating expenses result in recurring losses. Continued unprofitability limits retained earnings and reinvestment capacity, making long-term margin recovery and shareholder returns uncertain without sustained revenue scaling.
U.S. Sales Execution RiskReliance on U.S. hospital adoption makes delayed deals a material revenue timing risk. Persistent execution shortfalls reduce visibility on sales ramp, depress near-term cash receipts, and can slow the conversion of reimbursement gains into predictable, long-term commercial growth.
Impedimed Limited News
IPDQF FAQ
What was Impedimed Limited’s price range in the past 12 months?
Impedimed Limited lowest stock price was <$0.01 and its highest was $0.05 in the past 12 months.
What is Impedimed Limited’s market cap?
Impedimed Limited’s market cap is $24.62M.
When is Impedimed Limited’s upcoming earnings report date?
Impedimed Limited’s upcoming earnings report date is Aug 27, 2026 which is in 177 days.
How were Impedimed Limited’s earnings last quarter?
Impedimed Limited released its earnings results on Feb 20, 2026. The company reported -$0.004 earnings per share for the quarter, missing the consensus estimate of -$0.001 by -$0.003.
Is Impedimed Limited overvalued?
According to Wall Street analysts Impedimed Limited’s price is currently Undervalued.
Does Impedimed Limited pay dividends?
Impedimed Limited does not currently pay dividends.
What is Impedimed Limited’s EPS estimate?
Impedimed Limited’s EPS estimate is 0.
How many shares outstanding does Impedimed Limited have?
Impedimed Limited has 2,038,747,700 shares outstanding.
What happened to Impedimed Limited’s price movement after its last earnings report?
Impedimed Limited reported an EPS of -$0.004 in its last earnings report, missing expectations of -$0.001. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Impedimed Limited?
Currently, no hedge funds are holding shares in IPDQF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Impedimed Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$0.03 (66.30% Upside)
$0.03 (66.30% Upside)
Blogger Sentiment
Bullish
IPDQF Sentiment 91%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth AU$29.4K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-40.54%
12-Months-Change
Fundamentals
Return on Equity
-74.00%
Trailing 12-Months
Asset Growth
-12.99%
Trailing 12-Months
Company Description
Impedimed Limited
ImpediMed Limited, a medical software technology company, develops, manufactures, and sells bioimpedance spectroscopy (BIS) devices and software services in Australia, North America, and internationally. The company offers SOZO, a noninvasive BIS device for the assessment of lymphedema and fluid status monitoring of heart failure patients; SFB7, a single-channel, tetrapolar BIS device to analyze body composition in healthy individuals; and ImpediVET, a single-channel, tetrapolar (BIS) device that measures fluid status and tissue composition for veterinary applications. It sells its devices to hospitals and clinics. The company was incorporated in 1999 and is headquartered in Pinkenba, Australia.
IPDQF Company Deck
IPDQF Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The call balanced several strong operational, clinical and regulatory advances (93% reimbursement coverage, record revenue of $3.9M, ARR growth to $14.4M, FDA clearance, SOZO Pro launch, and major YoY and QoQ improvements in several metrics) against near‑term commercial execution challenges in the U.S. (weaker BCRL device sales, a decline in TCV, sales conversion delays due to hospital budget pressures, and elevated staff/FX headwinds). Financial discipline and cash flow improvement were emphasized, and a sizable pipeline and go‑to‑market initiatives position the company for potential recovery and growth.View all IPDQF earnings summariesIPDQF Stock 12 Month Forecast
Average Price Target
$0.03
▲(66.30% Upside)
Technical Analysis
Nova Eye Medical
―
Compumedics Limited
―
Cyclopharm Limited
―
Micro-X Ltd.
―
EMvision Medical Devices Ltd.
―
Ownership Overview
0.74% Insiders
<0.01% Mutual Funds
<0.01% Other Institutional Investors
99.26% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---